| Q60310408 | A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China |
| Q42952452 | A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections |
| Q90437573 | Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections: A Bayesian network meta-analysis of randomized clinical trials |
| Q42931315 | Clarification to the systematic review and meta-analysis involving tigecycline |
| Q92341709 | Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI) |
| Q37291338 | Current challenges in treating MRSA: what are the options? |
| Q36967265 | Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. |
| Q37904495 | Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis |
| Q26797442 | Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs |
| Q33642184 | Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial |
| Q37891606 | Efficacy and safety of tigecycline: a systematic review and meta-analysis |
| Q47129511 | Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials |
| Q36115632 | Excess deaths associated with tigecycline after approval based on noninferiority trials |
| Q36312071 | Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline |
| Q39222597 | The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis |
| Q55057742 | The role of tigecycline in the treatment of infections in light of the new black box warning. |
| Q82170910 | Tigecycline |
| Q36376443 | Tigecycline for the treatment of infections due to resistant Gram-positive organisms |
| Q37557875 | Tigecycline for treatment of intra-abdominal infections: a literature update |
| Q36663656 | Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections |
| Q33770721 | Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting |
| Q35876393 | Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections. |
| Q95793245 | Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria |